Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 30Lung Neoplasms 30Carcinoma, Non-Small-Cell Lung 26Leukemia, Myeloid, Acute 25Multiple Myeloma 22Breast Neoplasms 20Lymphoma 18Carcinoma, Renal Cell 17Urinary Bladder Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Myelodysplastic Syndromes 14Lymphoma, Large B-Cell, Diffuse 14Colorectal Neoplasms 14Pancreatic Neoplasms 11Neoplasm Metastasis 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Mouth Neoplasms 10Glioma 10Glioblastoma 10Burkitt Lymphoma 10Squamous Cell Carcinoma of Head and Neck 9Triple Negative Breast Neoplasms 8Sarcoma 8Rectal Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Melanoma 8Lymphoma, Non-Hodgkin 8Laryngeal Neoplasms 8Carcinoma 8

Interventions

Prednisone 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Specimen Handling 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Immunoglobulins, Intravenous 1Etoposide 1Cytarabine 1Carmustine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Autoimmune Diseases × Specimen Handling × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡